Comparative Pharmacology
Head-to-head clinical analysis: ALPHAZINE versus MOBAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAZINE versus MOBAN.
ALPHAZINE vs MOBAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist in the central nervous system, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and heart rate.
MOBAN (molindone) is an antipsychotic agent with mechanism of action not fully defined, but believed to involve dopamine D2 receptor blockade in the mesolimbic system, with minimal extrapyramidal effects due to weak D2 binding and possible serotonergic modulation.
Adults: IM/SC 10 mg every 4 hours as needed, maximum 40 mg/day; IV 5 mg over 1 minute, may repeat in 20-30 minutes, maximum 10 mg.
Oral: 50-100 mg/day in 3-4 divided doses, increase to 225 mg/day for severe conditions; maximum 400 mg/day. IM: 50-100 mg every 4-6 hours; maximum 400 mg/day.
None Documented
None Documented
5-7 hours; prolonged to 10-15 hours in renal impairment.
Terminal elimination half-life: 6-8 hours for parent drug; active metabolite (molindone) half-life ~12-15 hours; steady-state reached in 2-3 days.
Primarily renal (60-70% unchanged), 20-30% biliary/fecal as metabolites.
Renal: 70-80% as metabolites and unchanged drug; biliary/fecal: ~20%.
Category C
Category C
Antipsychotic
Antipsychotic